Seagen to highlight preclinical data for enfortumab vedotin and two novel antibody-drug conjugates at aacr annual meeting

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced data from intravesical instillation of enfortumab vedotin (ev) in a non-muscle invasive bladder cancer (nmibc) preclinical model in addition to preclinical data from sgn-alpv and sgn-b7h4v, two of its novel antibody-drug conjugates (adcs) that utilize the company's proprietary vedotin drug linker technology. these data will be presented at the american association for cancer research (aacr) annual meeting, taking place
SGEN Ratings Summary
SGEN Quant Ranking